BSE - Delayed Quote INR

Brooks Laboratories Limited (BROOKS.BO)

Compare
160.45
-3.25
(-1.99%)
At close: 2:15:00 PM GMT+5:30
Loading Chart for BROOKS.BO
DELL
  • Previous Close 163.70
  • Open 160.45
  • Bid --
  • Ask 160.45 x --
  • Day's Range 160.45 - 160.45
  • 52 Week Range 72.51 - 202.80
  • Volume 2,979
  • Avg. Volume 29,085
  • Market Cap (intraday) 4.211B
  • Beta (5Y Monthly) 1.54
  • PE Ratio (TTM) --
  • EPS (TTM) -7.69
  • Earnings Date Jan 29, 2025 - Feb 3, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. The company offers liquid and dry powder injection, carbapenem dry powder injectables, tablets, oral suspension, dry syrup, and eye/ear drops. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

www.brookslabs.net

293

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BROOKS.BO

View More

Performance Overview: BROOKS.BO

Trailing total returns as of 1/21/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BROOKS.BO
11.52%
S&P BSE SENSEX
3.08%

1-Year Return

BROOKS.BO
3.99%
S&P BSE SENSEX
5.80%

3-Year Return

BROOKS.BO
50.02%
S&P BSE SENSEX
27.54%

5-Year Return

BROOKS.BO
318.38%
S&P BSE SENSEX
82.62%

Compare To: BROOKS.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BROOKS.BO

View More

Valuation Measures

Annual
As of 1/20/2025
  • Market Cap

    4.30B

  • Enterprise Value

    4.36B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.46

  • Price/Book (mrq)

    7.26

  • Enterprise Value/Revenue

    5.61

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -21.46%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    817.16M

  • Net Income Avi to Common (ttm)

    -175.35M

  • Diluted EPS (ttm)

    -7.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.93M

  • Total Debt/Equity (mrq)

    8.60%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BROOKS.BO

View More

Company Insights: BROOKS.BO

Research Reports: BROOKS.BO

View More

People Also Watch